Ballicules.com

Darifenacin

ENABLEX

What it isM3-selective muscarinic antagonist; urgency and urge incontinence from overactive bladder.

Why this oneIts bladder-focused M3 selectivity aims to spare cognitive M1 effects better than oxybutynin.

What limits itConstipation and dry mouth remain prominent; urinary retention and CYP2D6 or CYP3A4 interactions can end treatment.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Overactive bladder (urge incontinence, urgency, frequency)Adults7.5 mg QD7.5-15 mg QD15 mg QD

Titration May increase to 15 mg QD as early as 2 weeks after starting.

Renal Undefined

Hepatic Moderate (Child-Pugh B): do not exceed 7.5 mg QD. Severe (Child-Pugh C): not recommended.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No human data; not teratogenic in animals. Use only if benefit outweighs fetal risk.

Lactation No human data; present in rat milk.

NO BOXED WARNINGS

Principal riskConstipation and dry mouth

Cost, est. cash$10–$300/month

Generic entry2015

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism4 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Darifenacin ballicule

Darifenacin ballicule: receptor binding, kinetics and half-life diagram

Open Darifenacin in the interactive console ↗

Memory aids: mascots and interaction avatars

Darifenacin ENABLEX mascot mnemonic cartoon
“Fenced-in Dairy Enabler”
“Red as a beet” crimson color theme → anticholinergic
Darifenacin CYP3A4 substrate avatar
CYP3A4 substrate

Open Darifenacin in the interactive console ↗